Trial Profile
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2026
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Casdatifan (Primary) ; Ipilimumab (Primary) ; Ivonescimab (Primary) ; Tivozanib (Primary) ; Volrustomig (Primary) ; Zimberelimab (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Acronyms ARC-20; eVOLVE
- Sponsors Arcus Biosciences
Most Recent Events
- 05 Aug 2026 According to Arcus Biosciences media release,In late-line ccRCC, updated data from the ARC-20 monotherapy cohorts, including overall survival data is expected in 2026.
- 05 Aug 2026 According to an Arcus Biosciences media release,In second-line IO-experienced ccRCC, more mature overall response rate data and initial PFS data, including Kaplan-Meier curve(s), for approximately 45 patients treated in the ARC-20 cohort evaluating casdatifan plus cabozantinib. All patients will have had at least 18 months of follow-up is expected in 2026.
- 05 Aug 2026 According to Arcus Biosciences media release, initial data from the ARC-20 cohorts evaluating casdatifan in early-line settings, including early efficacy data for the cohort evaluating casdatifan plus zimberelimab and early safety data for the cohort evaluating casdatifan plus zimberelimab plus ipilimumab in first-line ccRCCis expected in 2026.